User:Sagewall/sandbox/European Heart Journal Cardiovascular Pharmacotherapy

The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, English language, peer-reviewed journal with a specific focus on clinical cardiovascular pharmacology. It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area. The journal is a member of the European Heart Journal family

While the focus is on clinical topics, basic research articles from fields such as physiology and molecular biology which contribute to an understanding of cardiovascular drug therapy are also considered, such as articles relevant to new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects.

EHJ-CVP is an official journal of the European Society of Cardiology (ESC) and the ESC Working Group on Cardiovascular Pharmacotherapy and is aimed at clinicians, physicians, researchers, and policy makers.

The impact factor of the journal is 6.7, which make the journal number 1 within the cardiovascular pharmacology.

Professor Stefan Agewall at Oslo University is the Editor-in-Chief since the journal was started in 2015. The yearly number of issues increases and will be eight in 2022.

The journal is published by Oxford University Press. https://academic.oup.com/ehjcvp